Catch up on insights into the global development of breast cancer treatments in the global spotlight.
Feature|Articles|June 26, 2025
Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer
Author(s)Ashley Chan
Fact checked by: Kyle Doherty
As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.
Advertisement
Advertisement
Within the past decade, the HER2-positive breast cancer landscape has demonstrated significant improvements. However, coming off the heels of the
Related to this article
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement